ArticleDrug design, development and therapy2025
Cationic Liposome-Mediated Bcl-2 Gene Transfection in Bone Marrow Mesenchymal Stem Cells: A Novel Regenerative Approach for Spinal Cord Injury.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study explored a novel therapy for spinal cord injury (SCI) using cationic liposomes to deliver the anti-apoptotic Bcl-2 gene into rat bone marrow mesenchymal stem cells (BMSCs), followed by transplantation into a rat SCI model to evaluate its potential in promoting neural regeneration and enhancing SCI therapy. Methods: BMSCs were isolated and characterized for surface markers and differentiation potential, and transfected with Bcl-2 via cationic liposomes. A rat SCI model was established to assess the therapeutic effects of BMSCs and Bcl-2-BMSCs. Functional recovery was evaluated using the Basso, Beattie, and Bresnahan (BBB) scale and inclined plate test, while histopathology, Western blot, and real-time polymerase chain reaction (RT-PCR) analyses were performed to assess neural recovery. Nissl and myelin staining were used to evaluate neuronal and myelin recovery. Results: Following successful characterization of BMSCs and the spherical cationic liposomes (105 ± 1.3 nm, 18.65 ± 1.37 mV zeta potential), optimal transfection conditions were identified. Bcl-2-transfected BMSCs expressed high levels of Bcl-2 with low toxicity. In addition, the SCI results showed significant improvements in the BBB and inclined plate scores of rats in the BMSCs and Bcl-2-BMSCs groups compared to the model group (p< 0.01). HE-stained samples demonstrated that the secretion of Bcl-2 and BMSCs plays a crucial role in SC repair. Western blot results revealed an upregulation of proteins associated with neural recovery (Bcl-2, β-tubulin3, MAP2, NF-200, MBP) and a downregulation of the glial scar-associated protein GFAP in both the BMSCs and Bcl-2-BMSCs groups. Furthermore, Nissl staining and myelin staining showed that both the BMSCs and Bcl-2-BMSCs groups exhibited enhanced neuronal survival, inhibition of demyelination, and significant myelin regeneration. Conclusion: Transplantation of Bcl-2-transfected BMSCs represents a highly promising strategy that effectively promotes neural regeneration, inhibits scar formation, reduces demyelination, and enhances functional recovery, highlighting its potential for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.